The Path to Becoming Thailand’s Leader in Stem Cell Banking and Biotechnology at Global Standards of Medeze Group

The biotechnology industry has driven breakthroughs in modern medicine, a trend that became especially evident during the COVID-19 pandemic. Advances such as genetic engineering for vaccine development, molecular-level diagnostic testing, and laboratory-cultured stem cell therapies for COVID-19 patients have demonstrated the transformative potential of biotechnology.^[1] In the past, these innovations were largely limited to large corporations and required extensive research and testing over many years. However, rapid technological advancement has opened the door for new players to enter the market, accelerating innovation and expanding development opportunities. Combined with the growing global focus on healthcare, the biotechnology sector has become one of the most promising and closely watched industries today.

Stem Cells: The New Wave of Medical Treatment

One of the biotechnology fields that gained significant momentum during the COVID-19 outbreak is stem cell therapy, particularly treatments aimed at lung cell regeneration in COVID-19 patients. More than 70 research studies worldwide are currently investigating the use of stem cells in COVID-19 treatment.^[1] Interest in stem cells has been gaining attention before. Previously, stem cell applications were largely limited to blood-related diseases or aesthetic medicine. Click here to learn more about stem cells. คลิกรายละเอียดเพิ่มเติมเรื่องสเต็มเซลล์

Global Stem Cell Market Driving the Future of Alternative Medicine

The global stem cell market was valued at approximately USD 14 billion in 2020 and is projected to reach USD 26 billion by 2026, representing an average annual growth rate of over 10%.^[2] This growth aligns with the increasing number of studies reporting successful stem cell applications across a wide range of patient groups. A key driver behind this expansion is progress in stem cell isolation technologies, which now enable high-quality stem cells to be collected from umbilical cord and adipose tissues. These sources offer greater regenerative potential than traditional blood stem cells. In parallel, advancements in stem cell cryopreservation now enable long-term storage of up to 30 years, with a cell recovery success rate exceeding 95%.^[3]

The Biotechnology and Stem Cell Industry in Thailand

Thailand has also experienced strong growth in the biotechnology sector. According to data from the Department of Business Development, there are currently 81 registered businesses engaged in experimental research and development in biotechnology,^[4] of which 61 were established within the past five years. This trend mirrors global developments and aligns with Thailand's national strategy to become a regional medical hub. Under the Thailand International Health Hub Strategy (2017–2026), the country aims to meet rising healthcare demand from its aging population and international patients seeking high-quality medical services.^[5]

MEDEZE: Thailand's Path to Global Leadership in Stem Cell Banking and Biotechnology

Driven by these favorable conditions, Thailand's biotechnology industry has expanded rapidly. One of the country's pioneering institutions in this field, particularly in stem cell banking, is MEDEZE, formerly known as Bangkok Stem Cell. With over 11 years of experience, MEDEZE operates a laboratory specializing in the cultivation and long-term storage of blood stem cells in Thailand. The facility is certified by the American Association of Blood Banks (AABB) for its compliance with quality standards for stem cell processing, long-term preservation, and global transportation of stem cells derived from newborn umbilical cord blood. MEDEZE utilizes a controlled ultra-low temperature logistics system that maintains temperatures below freezing to preserve stem cell quality, enabling safe and effective transplantation worldwide.

With the goal of becoming a global leader in the stem cell industry by 2026, MEDEZE continuously develops itself across multiple dimensions to ensure corporate sustainability.

• For Customer Service

  For Customer Service, MEDEZE has pioneered customer-focused service innovation designed to meet real customer needs, with a strong emphasis on emotional well-being and long-term peace of mind. From the very beginning, MEDEZE became the first company in the world to offer lifetime stem cell storage, while most providers limited storage to only 20 years. Three years ago, as part of a strategic transition toward international-standard consolidated accounting in preparation for a future stock market listing, MEDEZE adjusted its lifetime storage model to 60 years. Even so, this remains a highly differentiated service innovation that delivers exceptional customer satisfaction. MEDEZE firmly believes that the longer stem cells are stored, the greater the likelihood they can be used to treat family members in the future. In addition, MEDEZE launched the Priority Package, designed to deliver the highest storage standards at a reasonable price. Through advanced financial planning, MEDEZE can fully refund storage fees to customers, a model that has been independently reviewed and verified by EY as financially feasible. This groundbreaking service innovation is unmatched in the industry. As a result, MEDEZE has been recognized by the global brand research firm Frost & Sullivan as “Thailand Stem Cell Banking Company of the Year” for four consecutive years.

  
• For Transparency in Corporate Governance, Finance, and Accounting

For Transparency in Corporate Governance, Finance, and Accounting, Medeze, with a strategic vision to become a leading biotechnology company in the region, places strong importance on financial transparency, accountability, and internationally recognized accounting standards. To ensure accuracy, auditability, and sustainable growth, MEDEZE has undergone continuous evaluation over the past three years by EY, DIA, and Yuanta, reinforcing confidence among stakeholders and investors.

• For Service Innovation

For Service Innovation, MEDEZE’s core strength lies in its continuous development of new services to improve the quality of life for people of all ages. The company has successfully developed stem cell isolation and expansion technologies that enable individuals of all ages to store their cells. MEDEZE has received approval from the Thai Food and Drug Administration (FDA) to assess the functional potential of white blood cells, including their strength and cancer-killing capability. Furthermore, MEDEZE is the first company in the world to introduce a long-term immune cell banking service, marking another global milestone in biotechnology services.

• For Research and Development

Artificial organ development by creation of corneal tissue using real human stem cells combined with collagen and 3D printing technology, currently in animal testing in collaboration with the Faculty of Veterinary Science, Chulalongkorn University

Enhanced killer cell targeting, improving the cancer-targeting ability of natural killer (NK) cells through receptor modification, in collaboration with the Chulabhorn Research Institute

Hair follicle cell culture innovation enables hair root cells to grow into hair strands and be preserved long-term for individuals experiencing hair thinning.

Clinical application of stored cells in collaboration with Phramongkutklao Hospital, MEDEZE is advancing the use of stored adipose-derived stem cells to treat knee osteoarthritis.

• Regional Market Expansion

  Regional Market Expansion: MEDEZE has expanded its presence across Asia-Pacific, with branches and laboratories in Taiwan, Singapore, Hong Kong, Cambodia, Vietnam, Indonesia, Myanmar, Australia, and New Zealand, and plans to further expand into Russia and the Middle East. As the first Thai biotechnology company to achieve such extensive regional expansion, growth, and innovation, MEDEZE has received consecutive regional awards from Frost & Sullivan: 2019 – Southeast Asia Stem Cell Banking Growth Excellence Leadership Award, 2020 – Southeast Asia Stem Cell Banking Technology Innovation Leadership Award